Mar 21
by
Vanessa Rohde
in
Flu Vaccines

FDA Committee Selects 2017-2018 Influenza Vaccine Strains

The Vaccines and Related Biological Products Advisory Committee of the US Food and Drug Administration has selected the influenza vaccine strains for the 2017-2018 influenza season, which begins in the fall of 2017.

The committee overwhelmingly voted to back the World Health Organization’s March 2 recommendations for influenza vaccine composition in the northern hemisphere (NH) for the upcoming influenza season. Three of the four recommended strains are unchanged from last season.

For trivalent influenza vaccines, the panel voted unanimously to include an A/Michigan/45/2015 (H1N1)pdm09-like virus; this is changed from A/California/7/2009 (H1N1)pdm09-like virus, but it is the same as 2017 southern hemisphere recommendations. The panel voted 10-yes, 0-no, with 1 abstention to include an A/Hong Kong/4801/2014 (H3N2)-like virus, with no change from the previous season’s NH recommendation; and 10-yes, 0-no, with 1 abstention to include a B/Brisbane/60/2008-like virus (B/Victoria lineage); there was no change from 2016-2017 NH recommendations.

For quadrivalent vaccines containing two influenza B viruses, the committee voted unanimously to add a B/Phuket/3073/2013-like virus (B/Yamagata) to the recommended trivalent vaccine strains. This recommendation was unchanged from the 2016-2017 NH recommendation.

Each country’s national or regional authorities approve the composition and formulation of vaccines used there.

Influenza Activity 2016-2017 Season

During the 2016-2017 influenza season, influenza A (H3N2) viruses were predominant in most countries. Most recent viruses were antigenically related to cell culture–propagated 3C.2a A/Hong Kong/4801/2014-like viruses.

Overall, influenza A(H1N1)pdm09 activity was low globally. Most recent A(H1N1)pdm09 viruses were indistinguishable from the present vaccine virus A/California/07/2009 and A/Michigan/45/2015 (vaccine virus for 2017 southern hemisphere).

B/Victoria/2/87 lineage viruses were the most predominant influenza B viruses in many countries in South America, Asia, and Eastern Europe. Most were closely related antigenically and genetically to B/Brisbane/60/2008 and B/Texas/2/2013.

In other regions, the levels of cocirculating B/Victoria and B/Yamagata lineage viruses were similar. Most recent B/Yamagata/16/88 lineage viruses were closely related antigenically and genetically to B/Phuket/3073/2013.

In the United States, there appears to be no clear way of predicting whether B/Victoria or B/Yamagata will be more prevalent in the coming season. Month by month, the two viruses cycle up and down, Jacqueline Katz, PhD, deputy director, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia, explained to the panel.

“Currently in the [United States]…B/Yamagata is edging out B/Victoria,” Dr Katz said.

Vaccine Effectiveness

The current influenza vaccine has been 48% (95% confidence interval [CI], 37% – 57%) effective in preventing influenza-related medical visits in all age groups, the CDC reported on February 17. According to the report, the vaccine was 43% (95% CI, 29% – 54%) effective against influenza A (H3N2) viruses and 73% (95% CI, 54% – 84%) effective against influenza B–related illness.

Read On

Mar 14
by
Marcus
in
Flu Vaccine 2017-2018 Flu Vaccines Influenza vaccines

Recommended composition of influenza virus vaccines for use in the 2017- 2018 northern hemisphere influenza season

Recommended composition of influenza virus vaccines for use in the 2017-
2018 northern hemisphere influenza season

March 2017

Recommended composition of influenza virus vaccines for use in the 2017-2018
northern hemisphere influenza season
Influenza A(H3N2) viruses predominated in most countries, with low levels of A(H1N1)pdm09 and
influenza B viruses also circulating during the period September 2016 – February 2017.
Influenza A(H1N1)pdm09 viruses were antigenically indistinguishable by post-infection ferret
antisera raised against current vaccine viruses A/California/7/2009 and A/Michigan/45/2015.
However, representative circulating viruses were poorly inhibited by some post-vaccination adult
human serum pools.
Influenza A(H3N2) viruses were associated with outbreaks in many countries. The majority of recent
viruses were antigenically related to cell culture-propagated 3C.2a A/Hong Kong/4801/2014-like
viruses. A(H3N2) viruses within the 3C.2a clade have become genetically diverse, although they
remain antigenically similar. The majority of recently circulating A(H3N2) viruses belong to subclade
3C.2a1.
Influenza B viruses of the B/Victoria/2/87 and the B/Yamagata/16/88 lineages co-circulated at
similar levels in some regions, but in many countries in South America, Asia and Eastern Europe,
B/Victoria/2/87 lineage viruses were predominant. Most B/Victoria/2/87 lineage viruses were
antigenically and genetically closely related to B/Brisbane/60/2008 and B/Texas/2/2013. The majority
of recent B/Yamagata/16/88 lineage viruses were antigenically and genetically closely related to
B/Phuket/3073/2013.
It is recommended that trivalent vaccines for use in the 2017-2018 northern hemisphere
influenza season contain the following:
– an A/Michigan/45/2015 (H1N1)pdm09-like virus;
– an A/Hong Kong/4801/2014 (H3N2)-like virus; and
– a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the
above three viruses and a B/Phuket/3073/2013-like virus.
Lists of egg- or cell culture-propagated candidate vaccine viruses (CVVs) suitable for use in human
vaccine production are available on the WHO website3
. A list of reagents for vaccine standardisation,
including those for this recommendation, can also be found on the WHO website. CVVs for zoonotic
influenza viruses are listed on the same website.

The World Health Organization (WHO) convenes technical consultations1 in February/March and
September each year to recommend viruses for inclusion in influenza vaccines2 for the northern and
southern hemisphere influenza seasons, respectively. This recommendation relates to the influenza
vaccines for use in the forthcoming northern hemisphere 2017-2018 influenza season. A
recommendation will be made in September 2017 relating to vaccines that will be used for the
southern hemisphere 2018 influenza season. For countries in tropical and subtropical regions,
epidemiological considerations influence which recommendation (northern hemisphere or southern
hemisphere) individual national and regional authorities consider appropriate.
Seasonal influenza activity, September 2016 – February 2017
Between September 2016 and February 2017 influenza activity was reported in Africa, the Americas,
Asia, Europe and Oceania. In general, activity was higher compared with the same period last year. In
the southern hemisphere, influenza activity was low in most countries, however, regional outbreaks
continued in South Africa during September and in Australia during September and October. In the
northern hemisphere, influenza activity began in Asia and Europe in October-November and had
increased in most countries by December. In many countries with tropical and subtropical climates,
influenza circulated during the entire reporting period.
Influenza A(H1N1)pdm09 viruses circulated at very low levels with a few exceptions. Influenza
A(H3N2) viruses were dominant in most countries and regional and widespread outbreaks were
reported in Asia, Europe, and North America. Influenza B viruses circulated at low levels in most
countries throughout the period while regional outbreaks were reported in Asia, western Africa and
the United States of America

Read On

Mar 14
by
Marcus
in
Flu Vaccine 2017-2018 Flu Vaccines Influenza vaccines

Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season

Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season

2 March 2017
It is recommended that trivalent vaccines for use in the 2017-2018 northern hemisphere influenza season contain the following:

an A/Michigan/45/2015 (H1N1)pdm09-like virus;
an A/Hong Kong/4801/2014 (H3N2)-like virus; and
a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus.

Read On

Mar 14
by
Marcus
in
Flu Vaccine 2017-2018 Flu Vaccines Influenza vaccines

FDA Committee Selects 2017-2018 Influenza Vaccine Strains

The Vaccines and Related Biological Products Advisory Committee of the US Food and Drug Administration has selected the influenza vaccine strains for the 2017-2018 influenza season, which begins in the fall of 2017.
The committee overwhelmingly voted to back the World Health Organization’s March 2 recommendations for influenza vaccine composition in the northern hemisphere (NH) for the upcoming influenza season. Three of the four recommended strains are unchanged from last season.
For trivalent influenza vaccines, the panel voted unanimously to include an A/Michigan/45/2015 (H1N1)pdm09-like virus; this is changed from A/California/7/2009 (H1N1)pdm09-like virus, but it is the same as 2017 southern hemisphere recommendations. The panel voted 10-yes, 0-no, with 1 abstention to include an A/Hong Kong/4801/2014 (H3N2)-like virus, with no change from the previous season’s NH recommendation; and 10-yes, 0-no, with 1 abstention to include a B/Brisbane/60/2008-like virus (B/Victoria lineage); there was no change from 2016-2017 NH recommendations.
For quadrivalent vaccines containing two influenza B viruses, the committee voted unanimously to add a B/Phuket/3073/2013-like virus (B/Yamagata) to the recommended trivalent vaccine strains. This recommendation was unchanged from the 2016-2017 NH recommendation.
Each country’s national or regional authorities approve the composition and formulation of vaccines used there.
Influenza Activity 2016-2017 Season
During the 2016-2017 influenza season, influenza A (H3N2) viruses were predominant in most countries. Most recent viruses were antigenically related to cell culture–propagated 3C.2a A/Hong Kong/4801/2014-like viruses.
Overall, influenza A(H1N1)pdm09 activity was low globally. Most recent A(H1N1)pdm09 viruses were indistinguishable from the present vaccine virus A/California/07/2009 and A/Michigan/45/2015 (vaccine virus for 2017 southern hemisphere).
B/Victoria/2/87 lineage viruses were the most predominant influenza B viruses in many countries in South America, Asia, and Eastern Europe. Most were closely related antigenically and genetically to B/Brisbane/60/2008 and B/Texas/2/2013.
In other regions, the levels of cocirculating B/Victoria and B/Yamagata lineage viruses were similar. Most recent B/Yamagata/16/88 lineage viruses were closely related antigenically and genetically to B/Phuket/3073/2013.
In the United States, there appears to be no clear way of predicting whether B/Victoria or B/Yamagata will be more prevalent in the coming season. Month by month, the two viruses cycle up and down, Jacqueline Katz, PhD, deputy director, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia, explained to the panel.
“Currently in the [United States]…B/Yamagata is edging out B/Victoria,” Dr Katz said.
Vaccine Effectiveness
The current influenza vaccine has been 48% (95% confidence interval [CI], 37% – 57%) effective in preventing influenza-related medical visits in all age groups, the CDC reported on February 17. According to the report, the vaccine was 43% (95% CI, 29% – 54%) effective against influenza A (H3N2) viruses and 73% (95% CI, 54% – 84%) effective against influenza B–related illness.

Read On

Apr 18
by
Marcus
in
Flu Vaccines Influenza

Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season

Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season

25 February 2016
It is recommended that trivalent vaccines for use in the 2016-2017 influenza season (northern hemisphere winter) contain the following:

an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Hong Kong/4801/2014 (H3N2)-like virus;
a B/Brisbane/60/2008-like virus.
It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus.

For more information
Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season – full report
pdf, 140kb
Questions and answers – Recommended composition of influenza virus vaccines
pdf, 69kb
Candidate vaccine viruses and potency testing reagents for development and production of vaccines for use in the northern hemisphere 2016-2017 influenza season
Influenza A(H1N1)pdm09
pdf, 172kb
Influenza A(H3N2)
pdf, 120kb
Influenza B Yamagata Lineage
pdf, 137kb
Influenza B Victoria Lineage
pdf, 126kb

Read On

Mar 27
by
Marcus
in
Flu Vaccines

Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season

It is recommended that trivalent vaccines for use in the 2015-2016 influenza season (northern hemisphere winter) contain the following:

  • an A/California/7/2009 (H1N1)pdm09-like virus;
  • an A/Switzerland/9715293/2013 (H3N2)-like virus;
  • a B/Phuket/3073/2013-like virus.

It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Brisbane/60/2008-like virus.

ABO Pharmaceuticals is now accepting orders for the 2015-2016 Influenza Season.  Please contact your Got Flu? Rep for pre-booking specials and get priority ship dates!

References:

1.) “WHO: Influenza” http://www.who.int

Read On

Feb 10
by
Marcus
in
Flu Vaccines

ABO Pharmaceuticals is proud to introduce PharmaJet

The first jet injector that is FDA approved for delivery of an influenza vaccine. AFLURIA® Influenza Vaccine is FDA Approved for use with PharmaJet’s Needle-Jet injectors.

The device delivers vaccines either intramuscularly or subcutaneously by means of a narrow, precise fluid stream syringe that delivers the medicine or vaccine through the skin.  PharmaJet has proven that it expands immunization coverage, eliminates the risk of needle sticks, reduces health care costs and offers a better patient experience. For more information on PharmaJet, please visithttp://www.abopharmaceuticals.com/pharmajet

References:

1.)   “Needle-Free” www.pharmajet.com

Read On

Jan 27
by
Marcus
in
Flu Vaccines

ABO Pharmaceuticals Receives Authorized Distributor Status for Stimate

CSL Behring awards ABO Pharmaceuticals Authorized Distributor for Stimate – The first and only high-concentration desmopressin acetate nasal spray that triggers your body’s natural ability to release von Willebrand factor (VWF), so that your blood can clot properly.

Read On

Jan 27
by
Marcus
in
Flu Vaccines

ABO Pharmaceuticals Receives Authorized Distributor Status for Cytogam

CSL Behring awards ABO Pharmaceuticals Authorized Distributor status for Cytogam – A critical life saving Product for organ transplant recipients

Read On

Feb 10
by
Marcus
in
Influenza

Announcing the Lanuch of ABO’s ‘Got FLu?’ Program

Our ‘got flu?’ Program eases the stress of the Flu Season by ensuring the availability of influenza vaccine from not one, but all major manufacturers, including afluria®, the Thimerosal-Free Flu Vaccine.

Read On